Immunomodulatory antibodies-based treatment, targeting the PD-1/PDL-1 pathway, displayed antitumor responses in patients with several cancer types, such as advanced melanoma, non-small cell lung cancer, or breast cancer [30]. This evidence concerns the gene CD274 and breast carcinoma.